Stocks · News reference
When Revolution Medicines' FDA Win Lifts Other Boats: SELLAS Life Sciences Stock Surges
SELLAS stock gains momentum following FDA approval for Revolution Medicines, highlighting SLS009 preclinical pancreatic cancer data.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Morgan Stanley Initiates Coverage On Revolution Medicines with Overweight Rating, Announces Price Target of $255
Morgan Stanley analyst Sean Laaman initiates coverage on Revolution Medicines (NASDAQ:RVMD) with a Overweight rating and announces Price Target of $255.
Stifel Maintains Buy on Revolution Medicines, Raises Price Target to $230
Reported Earlier, Revolution Medicines Lung Cancer Drug Shows 42% Response Rate In Early Trial
Revolution Medicines, Inc. (NASDAQ:RVMD), a global, commercial-stage oncology company dedicated to discovering, developing and delivering innovative medicines for patients with RAS-addicted cancers, today announced that
SELLAS Life Sciences Says Three Abstracts Evaluating SLS009, Potent, Selective CDK9 Inhibitor, In Preclinical Models Of PDAC Accepted For Poster Presentation At AACR Conference On Pancreatic Cancer
- Three posters to highlight preclinical activity of SLS009 (tambiciclib) across patient-derived KRAS mutant organoid models of pancreatic cancer – - Studies conducted in collaboration with the University of
SLS Stock Looks Like a $3 Billion Biotech Winner—This Short Seller Says the Market Has It Dangerously Wrong: 'Most Expensive Coin Flip' (UPDATED)
Short seller BMF Capital disclosed a short position in SELLAS Life Sciences, arguing the market has 'dangerously overvalued' the biotech.